White & Case Advises Graf Acquisition Corp. IV on Business Combination with NkGen Biotech, Inc.
1 min read
Global law firm White & Case LLP has advised Graf Acquisition Corp. IV, a New York Stock Exchange-listed special purpose acquisition company, on its entry into a definitive agreement for a business combination with NKGen Biotech, Inc., a leading clinical stage natural killer (NK) cell therapy company.
Upon the closing, Graf will be renamed NKGen Biotech, Inc., and is expected to be listed on the New York Stock Exchange under the ticker symbol NKGN.
NKGen Biotech, Inc. is a California-based clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK cell therapeutics.
The White & Case team was led by M&A partner James Hu, and included associates Hiroyuki Koda and Ren-Ann Wang (New York); Capital Markets partner Elliott Smith and associates Sarah Ross, Melissa Curvino and Guiying Ji (New York); Intellectual Property partner Andres Liivak (New York); Employment, Compensation & Benefits partner Victoria Rosamond, counsel Aaron Feuer (both in New York) and associate Otto Nunez-Montelongo (Washington, DC); Real Estate partner Steven Lutt (New York); Environment & Climate Change partner Seth Kerschner (New York); Tax partner David Dreier and associate Adriana Zhan (both in New York); Data, Privacy & Cybersecurity partner F. Paul Pittman (Washington, DC); and Technology Transactions counsel Ajita Shukla (Washington, DC) and associate Jordan Hill (New York). Law clerks Bridget Costello, Nana-Gyasi Kessie, Katherine Madriz and Julia Garcez also assisted on the matter.
For more information please speak to your local media contact.